Viking Therapeutics, Inc. Shareholders' Equity
Viking Therapeutics, Inc. (VKTX) had Shareholders' Equity of $408.32 million as of 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Balance Sheet › Equity › Equity, Including Portion Attributable to Noncontrolling Interest › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-07-29
- 2026-06-30: Stockholders' Equity Attributable to Parent $408.32M.
- 2026-03-31: Stockholders' Equity Attributable to Parent $501.92M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $639.06M.
- 2025-09-30: Stockholders' Equity Attributable to Parent $713.03M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $408.32M 10-Q · filed 2026-07-29 | |
| 2026-03-31 | $501.92M 10-Q · filed 2026-04-30 | |
| 2025-12-31 | $639.06M 10-Q · filed 2026-07-29 | |
| 2025-09-30 | $713.03M 10-Q · filed 2025-10-23 | |
| 2025-06-30 | $795.46M 10-Q · filed 2025-07-23 | |
| 2025-03-31 | $846.92M 10-Q · filed 2025-04-24 | |
| 2024-12-31 | $880.28M 10-K · filed 2026-02-11 | |
| 2024-09-30 | $911.45M 10-Q · filed 2024-10-23 | |
| 2024-06-30 | $920.98M 10-Q · filed 2024-07-24 | |
| 2024-03-31 | $933.89M 10-Q · filed 2024-04-25 | |
| 2023-12-31 | $348.42M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $368.24M 10-Q · filed 2023-10-25 | |
| 2023-06-30 | $386.12M 10-Q · filed 2023-07-26 | |
| 2023-03-31 | $134.06M 10-Q · filed 2023-04-26 | |
| 2022-12-31 | $145.32M 10-K · filed 2024-02-07 | |
| 2022-09-30 | $151.28M 10-Q · filed 2022-10-26 | |
| 2022-06-30 | $165.23M 10-Q · filed 2022-07-27 | |
| 2022-03-31 | $182.27M 10-Q · filed 2022-04-27 | |
| 2021-12-31 | $201.88M 10-K · filed 2023-02-10 | |
| 2021-09-30 | $213.12M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $224.97M 10-Q · filed 2021-07-28 | |
| 2021-03-31 | $237.22M 10-Q · filed 2021-04-28 | |
| 2020-12-31 | $244.34M 10-K · filed 2022-02-09 | |
| 2020-09-30 | $253.79M 10-Q · filed 2020-10-28 | |
| 2020-06-30 | $261.95M 10-Q · filed 2020-07-29 | |
| 2020-03-31 | $268.28M 10-Q · filed 2020-04-30 | |
| 2019-12-31 | $277.12M 10-K · filed 2021-02-17 | |
| 2019-09-30 | $283.49M 10-Q · filed 2019-11-05 | |
| 2019-06-30 | $288.35M 10-Q · filed 2019-08-01 | |
| 2019-03-31 | $294.57M 10-Q · filed 2019-05-02 | |
| 2018-12-31 | $297.75M 10-K · filed 2020-02-26 | |
| 2018-09-30 | $302.05M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $140.36M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $72.63M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $13.46M 10-K · filed 2019-03-13 | $13.46M 10-K · filed 2018-03-07 |
| 2017-09-30 | $2.23M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $6.59M 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $7.55M 10-Q · filed 2017-05-10 | |
| 2016-12-31 | $8.04M 10-K · filed 2018-03-07 | |
| 2016-09-30 | $10.22M 10-Q · filed 2016-11-10 | |
| 2016-06-30 | $12.79M 10-Q · filed 2016-08-11 | |
| 2016-03-31 | $5.77M 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $8.72M 10-K · filed 2017-03-21 | |
| 2015-09-30 | $13.27M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $17.39M 10-Q · filed 2015-08-14 | |
| 2015-03-31 | -$27.84M 10-Q · filed 2015-06-12 | |
| 2014-12-31 | -$22.13M 10-K · filed 2016-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |